Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

93.07 +0.15 (+0.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada
Health Canada has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for previously treated breast cancer patients. The approval... 
Via Benzinga
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
Pfizer Inc (NYSE: PFE) says it has begun late-stage testing for an oral drug that can be taken by persons who are exposed to the virus that causes COVID-19. What Happened: The New... 
Via Benzinga
Exposures COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?
The call for members of Congress to be banned from buying and selling stocks continues to heat up with a new report that seven members of the House of Representatives failed to... 
Via Benzinga
3 Relatively Safe Pharma Stocks You Can Buy Right Now
These stocks should be less volatile than many of the alternatives. 
Via The Motley Fool
EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile
NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-... 
Via Benzinga
Exposures COVID-19
Barron's Latest Picks And Pans: Apple, Bitcoin, a Goldman Sachs ETF, Nike And More
This weekend's Barron's cover story examines the t... 
Via Benzinga
Baidu, Gilead Sciences And Nvidia Stocks Provide Plays For Both Bulls And Bears: Here's How
Baidu. Inc (NASDAQ:BIDU), Gilead Sciences, Inc 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Gilead Churns Out Additional Trodelvy Data
Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic... 
Via Benzinga
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused... 
Via Benzinga
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
Which subset of the COVID-19 healthcare market will outperform over the next year? 
Via The Motley Fool
Exposures COVID-19
A Look Into Gilead Sciences Debt
Shares of Gilead Sciences (NASDAQ:GILD) rose by 7.09% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences... 
Via Benzinga
Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new... 
Via Benzinga
Could Moderna Take Down Gilead Sciences?
It's too early for a "yes" answer. But it's too premature for a "no" response as well. 
Via The Motley Fool
Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg
Gilead Sciences Inc (NASDAQ: GILD) persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Squibb & Co (NYSE: BMY) had won over immuno-... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Siemens' Fatty Liver Disease Blood Test Wins FDA De Novo Clearance
The FDA has granted clearance to a blood test from Siemens Healthineers (OTC: SMMNY) to provide an easier and potentially more accurate diagnostic alternative than an invasive... 
Via Benzinga
Exposures Product Safety
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
Why Fate Therapeutics Stock Is Sliding Today
The positive results the company announced after the bell yesterday didn't meet some lofty expectations. 
Via The Motley Fool
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Why NRx Pharmaceuticals Stock Jumped 11.8% Today
The company provided a positive update from a clinical study evaluating its COVID-19 therapy Zyesami. 
Via The Motley Fool
Exposures COVID-19
China's Red Ribbon School Provides a Refuge for Children Living With HIV
China's Red Ribbon School Provides a Refuge for Children Living With HIV 
Via News Direct
Topics Bonds Product Recall
Exposures Debt Markets Legal Product Safety
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and... 
Via Benzinga
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
Stocks That Hit 52-Week Highs On Monday
Before 10 a.m. ET on Monday, 71 companies hit new 52-week highs. Highlights: Apple (NASDAQ:AAPL) was the largest firm on a market cap basis to set a new 52-week... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.